Preliminary evidence of localizing CD8+ T-cell responses in COVID-19 patients with PET imaging

Front Med (Lausanne). 2024 May 15:11:1414415. doi: 10.3389/fmed.2024.1414415. eCollection 2024.

Abstract

The upper respiratory tract (URT) is the entry site for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), from where it further disseminates. Early and effective adaptive immune responses are crucial to restrict viral replication and limit symptom development and transmission. Current vaccines increasingly incorporate strategies to boost mucosal immunity in the respiratory tract. Positron emission tomography (PET) is a non-invasive technology that measures cellular responses at a whole-body level. In this case series, we explored the feasibility of [89Zr]Zr-crefmirlimab berdoxam PET to assess CD8+ T-cell localization during active COVID-19. Our results suggest that CD8+ T-cell distributions assessed by PET imaging reflect their differentiation and functional state in blood. Therefore, PET imaging may represent a novel tool to visualize and quantify cellular immune responses during infections at a whole-body level.

Keywords: CD8+ T-cells; PET imaging; SARS-CoV2; mucosal immunity; trafficking.

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study is sponsored and initiated by the Radboud University Medical Center. The tracer was provided by ImaginAb Inc. at no cost.